Meeting
2024 ASCO Annual Meeting
Evaluation of the study of control arms in randomized clinical trials of cancer.
Authors
Sandeep Kumar Jain
Brown University, Providence, RI
Sandeep Kumar Jain , Marjorie Glass Zauderer , Tarsheen Sethi , Martin W. Schoen , Sam Rubinstein , Ryan Huu-Tuan Nguyen , Seema Nagpal , Sanjay Mohan , Sathwik Madireddy , Mark Lythgoe , Wayne Liang , Amit Kulkarni , Shalin Kothari , Talal Hilal , Matthew James Hadfield , Gaurav Goyal , Teja Ganta , Bhagirathbhai R. Dholaria , Alaina J. Brown , Jeremy Lyle Warner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Quality Care/Health Services Research
Track
Care Delivery and Quality Care
Sub Track
Clinical Research Design
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 11023)
DOI
10.1200/JCO.2024.42.16_suppl.11023
Abstract #
11023
Poster Bd #
218
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
![Efficacy of systemic therapy following [<sup>177</sup>Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).](https://d201v5jt9ylckg.cloudfront.net/298/15164/217588/217588_A228_poster_pv.jpg)
Efficacy of systemic therapy following [177Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Louise Kathleen Kostos
Poster
2020 ASCO Virtual Scientific Program
Comparative effectiveness of systemic treatments for metastatic castration-sensitive prostate cancer: A parametric survival network meta-analysis of randomized controlled trials.
First Author: Lin Wang
Poster
2015 Gastrointestinal Cancers Symposium
Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer (mPC).
First Author: Daniel A. Goldstein
Poster
2014 ASCO Annual Meeting
Randomized phase II trial of weekly paclitaxel, carboplatin, cetuximab (PCC) versus cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF) in previously untreated patients with locally advanced head and neck squamous cell carcinoma.
First Author: Erminia Massarelli